MedTrace Logo

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of aspirin 75-100 mg/d for clinically indicated duration or for an additional 12 months will lead to an increased rate of primary patency, limb salvage, non-fatal myocardial infarction (MI), ischemic stroke, and survival, in patients receiving endovascular treatment of PAD at end of study treatment.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Clopidogrel

Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

DRUG

Acetylsalicylic acid (ASA)

Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Subhash Banerjee, MD · University of Texas Southwestern Medical Center

  • Subhash Banerjee, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-01-30
Completion
2020-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02217501 on ClinicalTrials.gov